<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378468</url>
  </required_header>
  <id_info>
    <org_study_id>The Berlin 'Cream&amp;Sugar' Study</org_study_id>
    <secondary_id>2009-010356-97</secondary_id>
    <nct_id>NCT01378468</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke</brief_title>
  <official_title>The Berlin 'Cream&amp;Sugar' Study: the Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-fasting triglyceride levels are thought to play a role in stroke. The investigators
      hypothesise that the results of a standardised oral triglyceride tolerance test in the
      subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of
      recurrent stroke within 12 months after the index event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since high postprandial triglycerides levels may be a risk factor for stroke, we use a
      combined oral triglyceride and glucose tolerance test in patients who had a first ischemic
      stroke. Follow-up after one year primarily assesses wether or not a recurrent stroke has
      occured. The glucose tolerance test is meant to identify patients with metabolic syndrome
      (and diabetes), since this condition is per se associated with increased levels of
      triglycerides. Potentially, the post-challenge triglyceride levels only play a role in
      patients without diabetes or metabolic syndrome. For further details see Ebinger et al. 'The
      Berlin 'Cream&amp;Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in
      patients after acute ischaemic stroke', IJS; 2010,5, 47-51.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Stroke</measure>
    <time_frame>outcome measure is assessed one year after first ischemic stroke.</time_frame>
    <description>The primary end-point of the study is a recurrent fatal or nonfatal stroke within the first 12 months after the event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>one year after first ischemic stroke</time_frame>
    <description>Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>one year after first ischemic stroke</time_frame>
    <description>cardiovascular death (death due to any cardiovascular or cerebrovascular event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIA</measure>
    <time_frame>one year after first ischemic stroke</time_frame>
    <description>transient ischemic attack</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">573</enrollment>
  <condition>First Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Patients with first ischemic stroke</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral triglyceride tolerance test (not a therapeutic &quot;intervention&quot; as such but a new diagnostic test)</intervention_name>
    <description>see Ebinger et al., IJS, 2010</description>
    <arm_group_label>Patients with first ischemic stroke</arm_group_label>
    <other_name>cream</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the study population consists of adults with first ischemic stroke within the last three to
        seven days (at time of testing).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  First ischemic stroke

          -  Incidence within less than 7 days

          -  Informed consent obtained

        Exclusion Criteria:

          -  Aphasia (if hampering informed consent)

          -  Swallowing disorder

          -  Pregnancy

          -  Renal or hepatic failure

          -  Pancreatitis

          -  Cholecystolithiasis

          -  Malabsorption

          -  Lactose intolerance

          -  Psychosis

          -  Drug and/or alcohol addiction

          -  Expected life expectancyr12 months

          -  Inability to sign informed consent

          -  Acute coronary syndrome

          -  Severe heart valve disorder

          -  Heart failure (NYHA III-IV)

          -  Severe infectious/rheumatic disease

          -  Sever metabolic disease

          -  No oral glucose tolerance test in case of known diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Ebinger</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Endres</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ebinger M, Heuschmann PU, Jungehuelsing GJ, Werner C, Laufs U, Endres M. The Berlin 'Cream&amp;Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in patients after acute ischaemic stroke. Int J Stroke. 2010 Apr;5(2):126-30. doi: 10.1111/j.1747-4949.2010.00399.x.</citation>
    <PMID>20446947</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Ebinger</investigator_full_name>
    <investigator_title>PD Dr. med. Dr. phil.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

